{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMOPF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMOPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMOPF\",,,,,undefined,":{"symbol":"CMOPF","market":"US","secType":"STK","nameCN":"Cosmo Pharmaceuticals NV","latestPrice":77.88,"timestamp":1753128000000,"preClose":77.88,"halted":0,"volume":0,"delay":15,"floatShares":8415540,"shares":16045886,"eps":4.628078,"marketStatus":"Closed","change":0,"latestTime":"07-21 16:00:00 EDT Delay","open":77.88,"high":77.88,"low":77.88,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":4.628078,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753171200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":77.88,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMOPF\",,,,,undefined,":{"symbol":"CMOPF","floatShares":8415540,"roa":"15.87%","roe":"29.31%","lyrEps":-0.338496,"shares":16045886,"dividePrice":2.396272,"high":77.88,"amplitude":0,"preClose":77.88,"low":77.88,"week52Low":55,"pbRate":"2.15","psRate":"4.01","week52High":95,"institutionHeld":0,"latestPrice":77.88,"eps":4.628078,"divideRate":0.030769,"volume":0,"delay":15,"ttmEps":4.628078,"open":77.88,"prevYearClose":66.9252,"prevWeekClose":77.88,"prevMonthClose":64.37,"prevQuarterClose":64.37,"fiveDayClose":77.88,"twentyDayClose":64.37,"sixtyDayClose":55},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CMOPF\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMOPF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533437236","title":"Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533437236","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533437236?lang=en_us&edition=fundamental","pubTime":"2025-05-05 12:59","pubTimestamp":1746421140,"startTime":"0","endTime":"0","summary":"Dublin, Ireland-- - Cosmo is attending this year’s Digestive Disease Week , held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders , innovators, and potential partners in AI and gastrointestinal  drug development.“DDW is the epicentre of innovation in GI, and we are here to make meaningful progress,” said Giovanni Di Napoli, CEO of Cosmo. “We’re engaging with some of the brightest minds and most visionary partners to drive our AI and drug development efforts forward. The future of GI is being shaped now, and Cosmo is committed to being a catalyst in that transformation.”In parallel, Cosmo has convened its AI Advisory Board at DDW, bringing together world-class experts to guide the company’s strategic priorities and fast-track development across its AI platform.Cosmo’s presence at the Digestive Disease Week underscores its long-term commitment to advancing GI care through a unique integration of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cosmo-highlights-strategic-ai-gi-045900226.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosmo-highlights-strategic-ai-gi-045900226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USA","BK4022","R","BK4007","CMOPF","BK4232"],"gpt_icon":0},{"id":"2532864954","title":"Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem","url":"https://stock-news.laohu8.com/highlight/detail?id=2532864954","media":"Newsfile","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532864954?lang=en_us&edition=fundamental","pubTime":"2025-05-02 13:08","pubTimestamp":1746162480,"startTime":"0","endTime":"0","summary":"Cerebro leverages advanced deep learning algorithms to analyse real-time endoscopic imaging, integrating seamlessly with multiple modalities – including White-Light, NBI, TXI, and BLI – to highlight critical anatomical landmarks and identify potential quality issues during EGD procedures. Using a robust, data-driven approach developed from extensively annotated datasets, Cerebro standardizes inspection protocols and generates detailed photo documentation, complete with coverage scores and procedural reports.With Cerebro, Cosmo’s real-time AI platform will extend its capabilities to the upper gastrointestinal tract, seamlessly complementing the established success in lower GI procedures. This release aligns with the ecosystem's aim to support all endoscopists with AI during their procedures, bridging the gap between technology innovation and its translation into better patient care.Saurabh Jejurikar, CEO of Endovision Limited, commented: “Achieving MDR certification underscores our team","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cosmo-announces-eu-mdr-certification-050800597.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosmo-announces-eu-mdr-certification-050800597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMOPF","BK4007","USA","BK4156"],"gpt_icon":0},{"id":"2531732393","title":"Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531732393","media":"Newsfile","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531732393?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:11","pubTimestamp":1745932260,"startTime":"0","endTime":"0","summary":"Dublin, Ireland-- - Following the recent CHMP opinion regarding the marketing authorization application for Winlevi  in Europe, Cosmo Pharmaceuticals N.V.  confirms that its financial guidance for 2025 remains unchanged.While the company is disappointed by the opinion, it maintains strong confidence in the clinical profile of Winlevi and its potential to address a significant unmet need in dermatology. The outcome of the CHMP opinion is not expected to have any material impact on the company’s current financial expectations.The Cosmo team is already preparing the re-examination submission. The company remains fully committed to securing access to Winlevi for patients in Europe.Cosmo will provide updates as the re-examination process progresses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cosmo-pharmaceuticals-confirms-financial-guidance-131100893.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosmo-pharmaceuticals-confirms-financial-guidance-131100893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","CMOPF","BK4087","BK4232","BK4022","R","USA","BK4007"],"gpt_icon":0},{"id":"2524132487","title":"Cosmo Appoints Federico Sommariva as Chief Legal Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2524132487","media":"Newsfile","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524132487?lang=en_us&edition=fundamental","pubTime":"2025-04-01 13:02","pubTimestamp":1743483720,"startTime":"0","endTime":"0","summary":"Dublin, Ireland-- - Cosmo Pharmaceuticals N.V.    today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico reports to the CEO and is member of the management team.Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan , with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome .Giovanni Di Napoli, CEO of Cosmo, commented: “We are delighted to welcome Federico as our new Chief Legal Counsel. With his expertise in corporate law and industry knowledge, he will play a crucial role in guiding our Company through an evolving regulatory landscape and supporting our long-term growth","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cosmo-appoints-federico-sommariva-chief-050200340.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosmo-appoints-federico-sommariva-chief-050200340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USA","CMOPF","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMOPF\",params:#limit:5,,,undefined,":[{"date":"2025-06-04","symbol":"CMOPF","amount":2.05,"announcedDate":"2025-03-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749043800000,"name":"Cosmo Pharmaceuticals NV","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-06","payableDate":"2025-06-05","currency":"EUR","dateTimestamp":1749009600000,"payDate":"2025-06-06"},{"date":"2024-07-10","symbol":"CMOPF","amount":2,"announcedDate":"2024-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-07-11","name":"Cosmo Pharmaceuticals NV","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-12","payableDate":"2024-07-11","currency":"EUR","dateTimestamp":1720584000000,"payDate":"2024-07-12"},{"date":"2023-05-31","symbol":"CMOPF","amount":1.05,"announcedDate":"2023-02-16","type":"dividend","market":"US","newRecordDate":"2023-06-01","defaultRemindTime":1685539800000,"name":"Cosmo Pharmaceuticals NV","recordDate":"2023-06-02","payableDate":"2023-06-01","currency":"EUR","dateTimestamp":1685505600000,"payDate":"2023-06-02"},{"market":"US","date":"2022-06-01","symbol":"CMOPF","amount":0.95,"defaultRemindTime":1654090200000,"name":"Cosmo Pharmaceuticals NV","recordDate":"2022-06-03","payableDate":"2022-06-02","currency":"EUR","type":"dividend","dateTimestamp":1654056000000},{"market":"US","date":"2022-03-31","symbol":"CMOPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1648699200000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMOPF\",market:\"US\",,,undefined,":[{"executeDate":"2022-06-01","recordDate":"2022-06-02","paymentDate":"2022-06-03","value":0.95,"currency":"EUR"},{"executeDate":"2023-05-31","recordDate":"2023-06-01","paymentDate":"2023-06-02","value":1.05,"currency":"EUR"},{"executeDate":"2024-07-10","recordDate":"2024-07-11","paymentDate":"2024-07-12","value":2,"currency":"EUR"},{"executeDate":"2025-06-04","recordDate":"2025-06-05","paymentDate":"2025-06-06","value":2.05,"currency":"EUR"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CMOPF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1751515200000}}}